Skip to main content

Advertisement

SpringerLink
Log in

The Role of Stereotactic Radiotherapy in the Treatment of Oligometastases

  • Lung Cancer (T Mekhail, Section Editor)
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

“Oligometastasis” describes a limited number of metastases arising typically from solid tumors whose behavior suggests an “intermediate” malignant state since it may potentially have a more favorable prognosis. Historically, selected patients with oligometastases often underwent surgical resection since anecdotal evidence suggested it could improve progression-free or overall survival. No prospective randomized trial evidence to date supports survival benefits from surgery. Short courses of highly focused, very high dose radiotherapy (stereotactic radiosurgery; stereotactic body radiotherapy) have emerged as a surgical surrogate to manage oligometastates. For solitary brain metastases, randomized study evidence supports stereotactic radiosurgery as part of their management because of overall survival benefits. Modeled after stereotactic radiosurgery, stereotactic body radiotherapy for extracranial metastases is becoming increasingly common given its efficacy and low toxicity, is an active area of clinical research, and is the subject of this review.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13:8–10.

    CAS  PubMed  Google Scholar 

  2. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322:494–500.

    Article  CAS  PubMed  Google Scholar 

  3. Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363:1665–72.

    Article  PubMed  Google Scholar 

  4. Barney DJ, Churchill EJ. Adenocarcinoma of the kidney with metastasis to the lung cured by nephrectromy and lobectomy. J Urol. 1939;42:269–76.

    Google Scholar 

  5. Aberg T, Malmberg KA, Nilsson B, et al. The effect of metastasectomy: fact or fiction? Ann Thorac Surg. 1980;30:378–84.

    Article  CAS  PubMed  Google Scholar 

  6. Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309–18.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Tomlinson JS, Jarnagin WR, DeMatteo RP, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol. 2007;25:4575–80.

    Article  PubMed  Google Scholar 

  8. The International Registry of Lung Metastases Writing Committee. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg. 1997;113:37–49.

    Article  Google Scholar 

  9. Treasure T, Fallowfield L, Lees B. Pulmonary metastasectomy in colorectal cancer: the PulMiCC trial. J Thorac Oncol. 2010;5:S203–6.

    Article  PubMed  Google Scholar 

  10. Leksell L. Stereotactic radiosurgery. J Neurol Neurosurg Psychiatry. 1983;46:797–803.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. Lax I, Blomgren H, Naslund I, et al. Stereotactic radiotherapy of malignancies in the abdomen. Methodological aspects. Acta Oncol. 1994;33:677–83.

    Article  CAS  PubMed  Google Scholar 

  12. Blomgren H, Lax I, Naslund I, Svanstrom R. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol. 1995;34:861–70.

    Article  CAS  PubMed  Google Scholar 

  13. Uematsu M, Shioda A, Tahara K, et al. Focal, high dose, and fractionated modified stereotactic radiation therapy for lung carcinoma patients: a preliminary experience. Cancer. 1998;82:1062–70.

    Article  CAS  PubMed  Google Scholar 

  14. Videtic G, Stephans K. The role of stereotactic body radiotherapy in the management of non-small cell lung cancer: an emerging standard for the medically inoperable patient? Curr Oncol Rep. 2010;12:235–41.

    Article  PubMed  Google Scholar 

  15. Shaw E, Scott C, Souhami L, et al. Radiosurgery for the treatment of previously irradiated recurrent primary brain tumors and brain metastases: initial report of Radiation Therapy Oncology Group protocol 90-05. Int J Radiat Oncol Biol Phys. 1996;34:647–54.

    Article  CAS  PubMed  Google Scholar 

  16. Corbin KS, Hellman S, Weichselbaum RR. Extracranial oligometastases: a subset of metastases curable with stereotactic radiotherapy. J Clin Oncol. 2013;31:1384–90.

    Article  CAS  PubMed  Google Scholar 

  17. Wulf J, Haedinger U, Oppitz U, et al. Stereotactic radiotherapy for primary lung cancer and pulmonary metastases: a noninvasive treatment approach in medically inoperable patients. Int J Radiat Oncol Biol Phys. 2004;60:186–96.

    Article  PubMed  Google Scholar 

  18. Hoyer M, Roed H, Traberg Hansen A, et al. Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol. 2006;45:823–30.

    Article  PubMed  Google Scholar 

  19. Hof H, Hoess A, Oetzel D, et al. Stereotactic single-dose radiotherapy of lung metastases. Strahlenther Onkol. 2007;183:673–8.

    Article  PubMed  Google Scholar 

  20. Katz AW, Carey-Sampson M, Muhs AG, et al. Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases. Int J Radiat Oncol Biol Phys. 2007;67:793–8.

    Article  PubMed  Google Scholar 

  21. Rusthoven KE, Kavanagh BD, Burri SH, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol. 2009;27:1579–84.

    Article  PubMed  Google Scholar 

  22. Rusthoven KE, Kavanagh BD, Cardenes H, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009;27:1572–8.

    Article  PubMed  Google Scholar 

  23. Okunieff P, Petersen AL, Philip A, et al. Stereotactic body radiation therapy (SBRT) for lung metastases. Acta Oncol. 2006;45:808–17.

    Article  PubMed  Google Scholar 

  24. Lee MT, Kim JJ, Dinniwell R, et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol. 2009;27:1585–91.

    Article  PubMed  Google Scholar 

  25. Milano MT, Katz AW, Zhang H, et al. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys. 2011;83:878–86.

    Article  PubMed  Google Scholar 

  26. Salama JK, Hasselle MD, Chmura SJ, et al. Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer. 2012;118:2962–70.

    Article  PubMed  Google Scholar 

  27. Bae SH, Kim MS, Cho CK, et al. High dose stereotactic body radiotherapy using three fractions for colorectal oligometastases. J Surg Oncol. 2012;106:138–43.

    Article  PubMed  Google Scholar 

  28. Bignardi M, Navarria P, Mancosu P, et al. Clinical outcome of hypofractionated stereotactic radiotherapy for abdominal lymph node metastases. Int J Radiat Oncol Biol Phys. 2011;81:831–8.

    Article  PubMed  Google Scholar 

  29. Casamassima F, Masi L, Menichelli C, et al. Efficacy of eradicative radiotherapy for limited nodal metastases detected with choline PET scan in prostate cancer patients. Tumori. 2011;97:49–55.

    CAS  PubMed  Google Scholar 

  30. Choi CW, Cho CK, Yoo SY, et al. Image-guided stereotactic body radiation therapy in patients with isolated para-aortic lymph node metastases from uterine cervical and corpus cancer. Int J Radiat Oncol Biol Phys. 2009;74:147–53.

    Article  PubMed  Google Scholar 

  31. Kim MS, Yoo SY, Cho CK, et al. Stereotactic body radiotherapy for isolated para-aortic lymph node recurrence after curative resection in gastric cancer. J Korean Med Sci. 2009;24:488–92.

    Article  PubMed Central  PubMed  Google Scholar 

  32. Kim MS, Choi C, Yoo S, et al. Stereotactic body radiation therapy inpatients with pelvic recurrence from rectal carcinoma. Jpn J Clin Oncol. 2008;38:695–700.

    Article  PubMed  Google Scholar 

  33. Casamassima F, Livi L, Masciullo S, et al. Stereotactic radiotherapy for adrenal gland metastases: University of Florence experience. Int J Radiat Oncol Biol Phys. 2012;82:919–23.

    Article  PubMed  Google Scholar 

  34. Chawla S, Chen Y, Katz AW, et al. Stereotactic body radiotherapy for treatment of adrenal metastases. Int J Radiat Oncol Biol Phys. 2009;75:71–5.

    Article  PubMed  Google Scholar 

  35. Holy R, Piroth M, Pinkawa M, et al. Stereotactic body radiation therapy (SBRT) for treatment of adrenal gland metastases from non-small cell lung cancer. Strahlenther Onkol. 2011;187:245–51.

    Article  PubMed  Google Scholar 

  36. Scorsetti M, Alongi F, Filippi AR, et al. Long-term local control achieved after hypofractionated stereotactic body radiotherapy for adrenal gland metastases: a retrospective analysis of 34 patients. Acta Oncol. 2012;51:618–23.

    Article  PubMed  Google Scholar 

  37. Torok J, Wegner RE, Burton SA, et al. Stereotactic body radiation therapy for adrenal metastases: a retrospective review of a noninvasive therapeutic strategy. Future Oncol. 2010;7:145–51.

    Article  Google Scholar 

  38. Milano MT, Katz AW, Muhs AG, et al. A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions. Cancer. 2008;112:650–8.

    Article  PubMed  Google Scholar 

  39. Milano MT, Katz AW, Schell MC, et al. Descriptive analysis of oligometastatic lesions treated with curative-intent stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 2008;72:1516–22.

    Article  PubMed  Google Scholar 

  40. Salama JK, Hasselle MD, Chmura SJ et al. Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer 2011;118:2962–2970.

  41. Kang JK, Kim MS, Kim JH, et al. Oligometastases confined one organ from colorectal cancer treated by SBRT. Clin Exp Metastasis. 2010;27:273–8.

    Article  PubMed  Google Scholar 

  42. Inoue T, Katoh N, Aoyama H, et al. Clinical outcomes of stereotactic brain and/or body radiotherapy for patients with oligometastatic lesions. Jpn J Clin Oncol. 2010;40:788–94.

    Article  PubMed  Google Scholar 

  43. Stinauer MA, Kavanagh BD, Schefter TE, et al. Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control. Radiat Oncol. 2011;6:34.

    Article  PubMed Central  PubMed  Google Scholar 

  44. Jereczek-Fossa BA, Beltramo G, Fariselli L, et al. Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer. Int J Radiat Oncol Biol Phys. 2012;82:889–97.

    Article  PubMed  Google Scholar 

  45. Wersäll PJ, Blomgren H, Lax I, et al. Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiother Oncol. 2005;77:88–95.

    Article  PubMed  Google Scholar 

  46. Svedman C, Sandström P, Pisa P, et al. A prospective phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma. Acta Oncol. 2006;45:870–5.

    Article  PubMed  Google Scholar 

  47. Nuyttens JJ, Prevost JB, Van der Voort van Zijp NC, et al. Curative stereotactic robotic radiotherapy treatment for extracranial, extrapulmonary, extrahepatic, and extraspinal tumors: technique, early results, and toxicity. Technol Cancer Res Treat. 2007;6:605–10.

    Article  CAS  PubMed  Google Scholar 

  48. Greco C, Zelefsky MJ, Lovelock M, et al. Predictors of local control after single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases. Int J Radiat Oncol Biol Phys. 2011;79:1151–7.

    Article  PubMed  Google Scholar 

  49. Milano M, Katz AW, Zhang H et al. Oligometastases treated with stereotactic body radiotherapy: Long-term follow-up of prospective. Int J Radiation Oncol Biol Phys 2012;83:e878–e886.

  50. Palma DA, Haasbeek CJA, Rodrigues GB et al. Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): Study protocol for a randomized phase II trial. BMC Cancer 2012;12:305–312.

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Gregory M. M. Videtic declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the author.

Author information

Authors and Affiliations

  1. The Cleveland Clinic, Cleveland, OH, USA

    Gregory M. M. Videtic

  2. Department of Radiation Oncology, Taussig Cancer Institute, The Cleveland Clinic, 9500 Euclid Avenue, Mailroom T28, Cleveland, OH, 44195, USA

    Gregory M. M. Videtic

Authors
  1. Gregory M. M. Videtic
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gregory M. M. Videtic.

Additional information

This article is part of the Topical Collection on Lung Cancer

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Videtic, G.M.M. The Role of Stereotactic Radiotherapy in the Treatment of Oligometastases. Curr Oncol Rep 16, 391 (2014). https://doi.org/10.1007/s11912-014-0391-3

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11912-014-0391-3

Keywords

Search

Navigation